Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
FDA approves Wegovy pill for weight loss - 2'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- 3Medtronic has 'significant firepower' for multiple acquisitions, executives say
- 4Solid Living Tips: Experiences from a Wellness Fan
- 5German-Polish man charged with calling for attacks on top politicians
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Creative Style: 10 Architects Reclassifying the Business
- Instructions to Investigate Different Open Record Extra Offers Actually
- America's Confided in Cooler in 2024
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- Instructions to Clean and Really focus on Your Lab Precious stone
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
